Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

“The native structure of κλ bodies is likely to ... Because TG-1801 only binds strongly to CD47 in the presence of CD19 on B cells, it is able to retain a fully functional Fc portion without ...

Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory domain. Quality control was assessed at different points in the ...

CLN-978 triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including ...